The emergence of molecular approaches to diagnosis and treatment has led many to believe that the era of the blockbuster, the one size fits all, premium priced, primary care product, is giving way to specialty products targeting genetically defined niche populations. In fact a new generation of blockbusters is coming to the fore—vaccines. This panel will review the key business and science drivers behind the resurgent vaccine market, as well as the opportunities and challenges facing large and small companies participating in this area.

• Highlight the re-emergence of vaccines as a major area of commercial and research interest
• Explain the business and economic drivers underlying this renewed interest
• Outline the key challenges facing large and emering companies seeking to participate in this area